Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.33 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.33 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.33 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | MMP12 | P39900 | 1/20 | 0.30 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.30 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12604366 | 0.82 | SMN1; SMN2 (0.32) | ALDH1A1SMN1; SMN2CA14CRBNTSHR | |
| SCHEMBL28073542 | 0.82 | KDM4E (0.38) | ALDH1A1SMN1; SMN2CA14CRBNTSHR | |
| SCHEMBL29106720 | 0.80 | DPP4 (0.41) | SMN1; SMN2CA14GRIN2DGRIN3BGRIN1 | |
| SCHEMBL104803 | 0.78 | — | — | |
| SCHEMBL41892 | 0.78 | — | — | |
| SCHEMBL30039818 | 0.78 | — | — | |
| SCHEMBL72838 | 0.78 | — | — | |
| SCHEMBL8218697 | 0.78 | CA14 (0.37) | SMN1; SMN2CA14GRIN2DGRIN3BGRIN1 | |
| SCHEMBL5579214 | 0.77 | — | — | |
| SCHEMBL1860453 | 0.77 | SMN1; SMN2 (0.37) | ALDH1A1SMN1; SMN2CA14GRIN2DGRIN3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250154219-A1 | PEPTIDE ANALOGS | ADEPTHERA LLC | 2025-05-15 | — | — | US | disclosed |
| US-12110318-B2 | Peptide analogs | ADEPTHERA LLC (US) | 2024-10-08 | — | — | US | disclosed |
| US-20220324935-A1 | PEPTIDE ANALOGS | ADEPTHERA LLC | 2022-10-13 | — | — | US | disclosed |
| US-11390657-B2 | Peptide analogs | ADEPTHERA LLC (US) | 2022-07-19 | — | — | US | disclosed |
| US-20200339649-A1 | PEPTIDE ANALOGS | ADEPTHERA LLC | 2020-10-29 | — | — | US | disclosed |
| EP-3645031-A1 | PEPTIDE ANALOGS | Adepthera LLC (US) | 2020-05-06 | — | — | EP | disclosed |
| US-10328116-B2 | Combinations of proteasome inhibitors and cyclic peptides | BIG DNA LTD (GB) | 2019-06-25 | — | — | US | disclosed |
| US-20190175687-A1 | Combination Therapy | BIG DNA LTD (GB) | 2019-06-13 | — | — | US | disclosed |
| US-20190153059-A1 | PEPTIDE ANALOGS | ADEPTHERA LLC | 2019-05-23 | — | — | US | disclosed |
| US-20190135886-A1 | GIP-GLP-1 DUAL AGONIST COMPOUNDS AND METHODS | ZEALAND PHARMA A/S (DK) | 2019-05-09 | — | — | US | disclosed |
| CN-102573845-A | Novel dicarboxylic acid linked amino acid and peptide prodrugs of opioids and uses thereof | SHIRE LLC | 2012-07-11 | — | — | CN | disclosed |
| EP-2453900-A1 | NOVEL CARBAMATE AMINO ACID AND PEPTIDE PRODRUGS OF OPIOIDS AND USES THEREOF | Shire LLC (US) | 2012-05-23 | — | — | EP | disclosed |
| EP-2413937-A1 | NOVEL DICARBOXYLIC ACID LINKED AMINO ACID AND PEPTIDE PRODRUGS OF OPIOIDS AND USES THEREOF | Shire LLC (US) | 2012-02-08 | — | — | EP | disclosed |
| US-20110190267-A1 | PRODRUGS OF OPIOIDS AND USES THEREOF | SHIRE PHARMACEUTICALS, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| WO-2011083304-A1 | PRODRUGS OF OPIOIDS AND USES THEREOF | SHIRE LLC (US) | 2011-07-14 | — | — | WO | disclosed |
| US-20110098278-A1 | GALANTAMINE AMINO ACID AND PEPTIDE PRODRUGS AND USES THEREOF | SHIRE LLC (US) | 2011-04-28 | — | — | US | disclosed |
| WO-2011007247-A1 | NOVEL CARBAMATE AMINO ACID AND PEPTIDE PRODRUGS OF OPIOIDS AND USES THEREOF | SHIRE LLC (US) | 2011-01-20 | — | — | WO | disclosed |
| US-20110015182-A1 | NOVEL CARBAMATE AMINO ACID AND PEPTIDE PRODRUGS OF OPIOIDS AND USES THEREOF | SHIRE LLC | 2011-01-20 | — | — | US | disclosed |
| US-20100286186-A1 | NOVEL DICARBOXYLIC ACID LINKED AMINO ACID AND PEPTIDE PRODRUGS OF OPIOIDS AND USES THEREOF | SHIRE LLC (US) | 2010-11-11 | — | — | US | disclosed |
| WO-2010112942-A1 | NOVEL DICARBOXYLIC ACID LINKED AMINO ACID AND PEPTIDE PRODRUGS OF OPIOIDS AND USES THEREOF | SHIRE LLC (US) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339649-A1 | PEPTIDE ANALOGS | RAMP1, RAMP2, RAMP3 | ALDH1A1 4707/4885SMN1; SMN2 4342/4885CA14 4567/4885 |
| US-20100286186-A1 | NOVEL DICARBOXYLIC ACID LINKED AMINO ACID AND PEPTIDE PRODRUGS OF OPIOIDS AND USES THEREOF | VIP, OPRL1, OPRK1 | ALDH1A1 1313/4885SMN1; SMN2 2249/4885CA14 1578/4885 |
| US-20110015182-A1 | NOVEL CARBAMATE AMINO ACID AND PEPTIDE PRODRUGS OF OPIOIDS AND USES THEREOF | OPRL1, OPRM1, DNPEP | ALDH1A1 2705/4885SMN1; SMN2 3176/4885CA14 454/4885 |
| US-12110318-B2 | Peptide analogs | RAMP1, RAMP3, RAMP2 | ALDH1A1 4712/4885SMN1; SMN2 4521/4885CA14 4559/4885 |
| US-20110098278-A1 | GALANTAMINE AMINO ACID AND PEPTIDE PRODRUGS AND USES THEREOF | PEPD, VIP, GALR1 | ALDH1A1 3187/4885SMN1; SMN2 1522/4885CA14 2301/4885 |
| US-20220324935-A1 | PEPTIDE ANALOGS | RAMP1, RAMP2, RAMP3 | ALDH1A1 4707/4885SMN1; SMN2 4342/4885CA14 4567/4885 |
| US-10328116-B2 | Combinations of proteasome inhibitors and cyclic peptides | PSMB3, PSMA3, PSMA6 | ALDH1A1 1474/4885SMN1; SMN2 3139/4885CA14 499/4885 |
| US-20250154219-A1 | PEPTIDE ANALOGS | RAMP1, RAMP2, RAMP3 | ALDH1A1 4707/4885SMN1; SMN2 4342/4885CA14 4567/4885 |
| US-20190153059-A1 | PEPTIDE ANALOGS | RAMP1, RAMP2, RAMP3 | ALDH1A1 4707/4885SMN1; SMN2 4342/4885CA14 4567/4885 |
| US-20110190267-A1 | PRODRUGS OF OPIOIDS AND USES THEREOF | OPRK1, OPRL1, OPRM1 | ALDH1A1 225/4885SMN1; SMN2 1164/4885CA14 2716/4885 |
| US-20190175687-A1 | Combination Therapy | PSMA6, PSMB3, PSMB6 | ALDH1A1 1272/4885SMN1; SMN2 3533/4885CA14 489/4885 |
| US-11390657-B2 | Peptide analogs | RAMP1, RAMP3, RAMP2 | ALDH1A1 4712/4885SMN1; SMN2 4521/4885CA14 4559/4885 |
| US-20190135886-A1 | GIP-GLP-1 DUAL AGONIST COMPOUNDS AND METHODS | GLP1R, GIPR, GCGR | ALDH1A1 4412/4885SMN1; SMN2 1960/4885CA14 3889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.